Division of Solid Tumor Oncology: Early Drug Development Service

Early Drug Development Service Chief David Hyman

Nearly every treatment that is available to patients today has come about because of a clinical trial. At MSK, we strive to lead the way in every stage of the research process.

The Early Drug Development Service (EDD) represents MSK’s commitment to provide access to exciting new therapies for our adult and pediatric patients from the very earliest stages when they first enter the clinic.

In our Service, our doctors and scientists work together to expand our drug development initiatives and our patients benefit from close communication with their healthcare team.

The EDD supports the Department of Medicine, the Human Oncology & Pathogenesis Program, and the Sloan Kettering Institute, and works closely with the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Precision Pathology Biobanking Center, Functional Genomics Initiative, the Center for Epigenetics Research, and the Brain Tumor Center, among others.